Gunderson Dettmer Advises Theravance on Follow-on Public Offering
Gunderson Dettmer advised Theravance Biopharma, Inc., a diversified biopharmaceutical company focused on the discovery, development and commercialization of organ-selective medicines, in a $100.5M follow-on public offering.
The funds will support continued development of three clinical programs and provide working capital for advancing other clinical or preclinical product candidates and acquisitions of other technology or drug candidates. Gunderson Dettmer has represented Theravance since 2014 and in previous follow-on offerings.
The team advising Theravance included IPO/public companies chair Jeff Vetter, corporate partner David Young, IPO partner Colin Conklin, and associates Jessica Jeong, Frank Strumolo, Elizabeth Gimzewski and Daniel Reichert.